Egg Donor Agreement

An egg donor agreement records an egg donor's and intended parent or parents' pre-retrieval intentions concerning donation, parentage, compensation and expenses, medical-cost protection, information sharing, contact, and control of retrieved eggs and resulting embryos, subject to governing law and separate clinical consent.

A useful document turns the parties' actual arrangement into measurable duties, approvals, timing, remedies, and a reliable execution record. Its terms should be reconciled to the transaction rather than copied from an unrelated form.

• A known or directed egg donor and intended parent or parents want a written record of donative intent and expectations before medication or retrieval
• A clinic, egg bank, or matching program requires counsel-reviewed terms covering compensation, expenses, medical risks, insurance, records, contact, and ownership or disposition after retrieval
• The parties need to distinguish the donor's rights in her body and clinical care from the intended parents' control over eggs retrieved and embryos later created, to the extent applicable law permits
• A cross-state arrangement requires counsel to reconcile the law of the donor's residence, intended parents' residence, clinic and retrieval location, storage location, anticipated transfer or birth, and any parentage forum

The document name alone does not determine the right structure. Consider a different instrument or qualified legal review when any of these conditions applies:

• Do not use a national form without current reproductive-law advice for every materially connected state; rules on donative intent, parentage, compensation, formalities, brokers, clinic licensing, identity disclosure, records, and enforceability vary and may change.
• Do not use the agreement as the donor's informed consent to medication, anesthesia, egg retrieval, genetic testing, or another medical procedure, or to require the donor to continue a cycle after withdrawing clinical consent; treatment decisions remain with the donor and licensed clinicians.
• Do not use it as a fertility-clinic services agreement, donor-eligibility determination, laboratory order, privacy authorization, cryostorage contract, embryo-disposition directive between intended parents, surrogacy agreement, adoption, birth record, or parentage judgment.
• Do not promise anonymity or future noncontact without accounting for applicable disclosure and record laws, clinic or bank policies, later medical-information needs, direct-to-consumer genetic testing, and the fact that a resulting person is not ordinarily a party to the agreement.
• Do not describe payment as the purchase price of eggs, embryos, parental rights, a pregnancy, or a child, or condition compensation on egg count, fertilization, embryo quality, genetic traits, pregnancy, live birth, or the characteristics of any resulting person.

Record exact facts before clauses are written. Names, authority, dates, amounts, defined terms, dependencies, and incorporated materials should be verifiable and consistent.

• The donor, intended parent or parents, spouses or partners whose consent or participation may matter, separate counsel, agency or facilitator, clinic, physician, laboratory, tissue or egg bank, escrow holder, insurer, and emergency contacts
• Every connected jurisdiction and event, including residence, recruitment, matching, signing, screening, medication, monitoring, retrieval, fertilization, storage, transfer, anticipated pregnancy and birth, plus any required license, registration, witness, notary, counsel, or timing rule
• Whether the arrangement is known, directed, identity-release, open, semi-open, or intended to be nonidentified; what identifying and nonidentifying information may be exchanged; and what state law, clinic policy, or later genetic matching may override expectations
• The donor's relevant medical, reproductive, social, and family history; infectious-disease and genetic screening; truthful update duties; test-result access; incidental or later findings; and the method for communicating material health updates without turning the contract into medical consent
• The anticipated stimulation and retrieval cycle, medication and appointment logistics, travel and companion needs, cancellation criteria, and the donor's continuing authority to accept, refuse, or withdraw consent to care in consultation with clinicians
• Base compensation if lawful, reimbursement categories, lost wages, travel, lodging, meals, childcare, medications, screening and legal fees, payment milestones, cancellation and proration rules, tax treatment, receipts, escrow or trust administration, and prohibited outcome- or trait-based payment
• Primary health-plan terms and exclusions, complication or supplemental policy, effective and runout periods, premiums, deductibles, copayments, liens, uncovered medical and behavioral-health care, disability or lost income, claims cooperation, and the payer of last resort
• The eggs expected to be retrieved, the intended recipients, permissible fertilization and reproductive uses, allocation among intended parents, clinic and storage instructions, and who controls resulting embryos, with unused-embryo decisions left to separate directives by persons who hold legal control
• Contact during the cycle and after retrieval, future medical updates, requests from a resulting person, donor-conceived siblings, intermediaries or registries, confidentiality exceptions, social media, records custody and retention, and procedures when a clinic or party cannot be located

These decisions shape the allocation of responsibility and should not be left for boilerplate to decide:

• Which jurisdictions are connected, whether their parentage and donor rules recognize the proposed structure, and which signing, timing, witness, notarization, counsel, license, clinic, tissue-bank, or court requirements apply
• Who is a donor rather than an intended parent, what evidence will establish donative intent before use, whether any spouse or partner must participate, and whether counsel should obtain a parentage judgment despite the contract
• What clinical decisions remain solely with the donor and treating team, when either side may cancel, how withdrawal before or after medication affects only lawful accrued payment and expenses, and how emergency and follow-up care will be handled
• Which compensation and reimbursement terms are lawful, how milestones and proration avoid payment for outcome or traits, when escrow is funded, and who handles taxes, documentation, and benefit consequences
• Which policy covers stimulation, retrieval and later complications, how long protection lasts, who pays premiums and out-of-pocket costs, what happens after denial or exhaustion, and whether disability, life, travel, or psychological coverage is needed
• Which medical and genetic facts and test results are required, who may access them, how new material diagnoses are exchanged, whether additional tests or research are allowed, and how sensitive records are retained and secured
• Whether contact is direct or intermediated and whether identity release is planned, how requests from a resulting person are handled, and how the parties will communicate that anonymity cannot be guaranteed by contract
• When control of retrieved eggs transfers, which recipients and uses are authorized, whether donation to another person or research is allowed, and which separate clinic and embryo-disposition documents control embryos after fertilization, storage, separation, death, nonpayment, or completion

• Parties, donative intent, absence of intent to parent, intended recipients, connected jurisdictions, representations, conditions precedent, and an express statement that legal parentage is determined by applicable law and any required judicial process
• Voluntary execution and independent advice, execution before medication or procedure where required or prudent, required signatures, witnesses or notarization, conflicts disclosures, interpreter access, copies, amendments, and precedence among coordinated documents
• Medical autonomy clause stating that the donor selects whether to consent to or continue treatment, may ask questions and consult independent clinicians, and is not liable merely for following medical advice or withdrawing clinical consent, while addressing notice and accrued payment consequences without coercion
• Clinical coordination that defers eligibility, medication, monitoring, anesthesia, retrieval, emergency, cancellation, and aftercare decisions to the donor and treating clinicians and makes no promise about egg number, quality, fertilization, embryo development, pregnancy, or birth
• Compensation and documented expenses only as lawful, with payment tied to time, inconvenience, risk, and completed milestones rather than outcome or genetic traits; escrow or trust mechanics; prorating after cancellation; taxes; and survival of accrued obligations
• Insurance and complications plan covering policy review, exclusions, effective date, premiums, deductibles, copayments, liens, uncovered care, psychological care, disability and lost wages, claim control, coverage after retrieval, and a contractual backstop where lawful
• Truthful health and genetic history, screening cooperation, access to the donor's own results, limits on disclosure, clinically significant later updates, reciprocal notification channels, and permission boundaries for additional tests, stored samples, research, or unrelated secondary use
• Identity, confidentiality, records, and contact terms that distinguish current preferences from legal guarantees; reserve disclosures required by law or needed for care; address requests by a resulting person; and acknowledge that genetic testing can defeat practical anonymity
• Release and control of retrieved eggs for the stated intended recipients and uses, including fertilization, storage, transport, transfer, and lawful donation or disposition, while stating that the donor controls her body and that intended-parent or clinic embryo directives govern embryos after creation
• Cycle cancellation, withdrawal, failed retrieval, serious adverse event, death or incapacity, relationship change, unused medication and samples, record preservation, dispute process, remedies that cannot compel medical performance, governing law, severability, and termination

Every provision should use the same parties, dates, standards, defined terms, and document hierarchy. A clause that is reasonable by itself can still create a conflict when it is not reconciled with payment, default, termination, or another exhibit.

1. 01Describe the intended result and the relationship in plain language.
2. 02Confirm parties, authority, governing jurisdiction, dates, money, property, services, and approvals.
3. 03Resolve the key decisions and identify every schedule, exhibit, disclosure, consent, or filing.
4. 04Draft the provisions as one consistent system, then review the complete execution set before signature.

An egg-donation cycle combines a medical relationship, a donative-intent and parentage record, financial promises, privacy expectations, and clinic or tissue-bank regulation, but one agreement cannot perform every function. Federal rules govern communicable-disease screening, testing, labeling, and records for reproductive tissue, while state law may impose different definitions, formalities, compensation limits, parentage evidence, identity-release choices, and clinic duties. Key risks include coercive continuation terms, execution after medication starts, inaccurate history, unreviewed insurance exclusions, uncovered complications, outcome-based payment, conflicting clinic forms, ambiguous control of eggs or embryos, missing spouse consent, unreliable anonymity promises, stale contact information, and assuming that a contract alone establishes nonparentage everywhere.

The main agreement may establish the framework while schedules, exhibits, disclosures, consents, or operational records supply transaction-specific details.

• Separate-counsel engagement letters, identity and capacity records, interpreter confirmation, required statutory notices, agency or facilitator disclosures, and witnessed or notarized signature pages
• Clinic treatment consents, donor-eligibility determination, medical and psychological screening confirmations, infectious-disease and genetic test documentation, medication plan, anesthesia and retrieval consents, emergency plan, and narrowly tailored privacy authorizations
• Compensation and expense schedule, escrow or attorney-trust agreement if used, funding confirmation, receipts and wage-loss records, cancellation or proration schedule, and tax or public-benefit notices
• Health-plan documents and exclusion review, complication or supplemental policy, proof of effective dates and premiums, disability or lost-income coverage if selected, claims instructions, lien information, and uncovered-cost undertaking
• Egg-bank, laboratory, transport, clinic, and cryostorage agreements; chain-of-custody and identification records; intended-recipient instructions; fertilization authorizations; and separate embryo-storage and disposition directives
• Donor profile and family history, identity-release or nonidentified declaration, permitted contact protocol, medical-update registry instructions, record-retention plan, and documented contact details for successor clinics, banks, counsel, or intermediaries
• Any parentage petition or judgment, birth-record forms, intended-parent consents to assisted reproduction, spouse or partner consents, and related donor, sperm, embryo, or gestational-carrier agreements

Each incorporated document should be identified precisely, use the same names and effective date, and follow a stated order of precedence if terms conflict.

Before signing or medication, reproductive-law counsel should map every connected state, confirm the donor and intended-parent status and formalities, and reconcile the agreement with clinic, FDA donor-eligibility, genetic-testing, privacy, insurance, escrow, egg-bank, storage, embryo-disposition, and parentage records. Obtain the donor's separate clinical consent directly through licensed providers; document payment and complication protection without penalizing medical refusal; preserve identity and medical-history records through the responsible clinic or bank; and complete any court or vital-record process counsel identifies. NOMOS provides general drafting information, not legal, medical, genetic, psychological, insurance, tax, benefits, or financial advice; it does not represent any party, determine suitability, obtain informed consent, verify coverage, hold escrow, guarantee anonymity or treatment outcome, or establish parentage.

• Confirm legal names, roles, capacity, addresses, and signing authority
• Reconcile dates, amounts, definitions, cross-references, schedules, and exhibits
• Confirm that duties, deadlines, approvals, acceptance standards, and payment triggers are measurable
• Check that default, termination, remedies, and surviving obligations work together
• Complete jurisdiction-specific forms, notices, witnesses, notarization, filings, or professional review when applicable
• Deliver and preserve the complete signed package with its incorporated documents

These sources provide federal, state-resource, regulatory, or institutional context. They do not replace checking the law and required forms applicable to the parties, transaction, and governing jurisdiction.

1. Source 1

   21 CFR Section 1271.75 — How do I screen a donor?

   Electronic Code of Federal Regulations. Current federal rule requiring review of relevant medical records for communicable-disease risks and clinical evidence, with additional screening for donors of reproductive cells or tissue. It supports treating screening and eligibility as regulated clinical processes rather than contractual warranties.

2. Source 2

   21 CFR Section 1271.85 — What donor testing is required for different types of cells and tissues?

   Electronic Code of Federal Regulations. Current federal rule specifying communicable-disease testing for cell and tissue donors, including additional requirements for reproductive cells or tissue. The rule helps distinguish mandatory establishment testing from broader genetic screening selected under state law and clinic policy.

3. Source 3

   21 CFR Section 1271.55 — Accompanying and retained donor-eligibility records

   Electronic Code of Federal Regulations. Current federal rule requiring an identification code, eligibility statement, and records summary to accompany covered tissue, excluding identifying personal information from accompanying records and requiring testing, screening, and eligibility records to be retained for at least ten years after administration or the latest relevant disposition event.

4. Source 4

   California Family Code Section 7613

   California Legislative Information. Current California statute addressing intended-parent consent and donor status. It provides that an ova provider for another person is not treated as the natural parent absent satisfactory evidence of a contrary shared intent, and requires an original provider's written consent when another person later provides the ova, semen, or embryos.

5. Source 5

   New York Family Court Act Section 581-202 — Parentage proceeding after assisted reproduction

   New York State Senate. Current official New York statute describing sufficient proof of donative intent, including clinic or storage documentation or a donor record, and enhanced signing formalities when donation does not occur through a facility or practitioner. It also authorizes a judgment establishing intended parentage and donor nonparentage.

6. Source 6

   New York Family Court Act Section 581-501 — Reimbursement

   New York State Senate. Current official New York statute providing that a donor who entered a valid donor agreement may receive reimbursement from intended parents for economic losses connected with donation that result from retrieval or storage of gametes or embryos.

7. Source 7

   New York Family Court Act Section 581-502 — Compensation

   New York State Senate. Current official New York statute allowing reasonable, good-faith donor compensation based on medical risks, discomfort, inconvenience, and responsibilities, while forbidding payment to purchase gametes or release parental interests and forbidding compensation based on purported quality or genome-related, genotypic, or phenotypic traits.

8. Source 8

   10 NYCRR Section 52-8.6 — Required laboratory tests

   New York State Department of Health. Current official New York regulation requiring reproductive-tissue donor testing and written oocyte-donor testing policies, addressing certain family-history or background-linked carrier testing, and making donor test results available on request to donors and physicians using the reproductive tissue.

9. Source 9

   10 NYCRR Section 69-11.14 — Ova donation guidelines

   New York State Department of Health. Official New York regulation requiring assisted-reproduction providers to maintain donor-selection and evaluation policies consistent with Part 52 and Department guidance and to give Department ova-donation informational material in hard copy to prospective donors who contact the provider.

10. Source 10

    Washington RCW 26.26A.815 — Donor identity-disclosure declaration

    Washington State Legislature. Current official Washington statute requiring a licensed gamete bank or fertility clinic that collects gametes to inform the donor about identity-disclosure choices and obtain a witnessed or notarized declaration, with an option to change a present nondisclosure choice to disclosure.

11. Source 11

    Washington RCW 26.26A.820 — Disclosure to a donor-conceived child

    Washington State Legislature. Current official Washington statute governing a licensed gamete bank's or clinic's good-faith disclosure efforts after qualifying requests, including access to nonidentifying medical history regardless of the donor's identity declaration and source-facility contact information in transfer cases.

12. Source 12

    Washington RCW 26.26A.825 — Donor recordkeeping duty

    Washington State Legislature. Current official Washington statute requiring licensed gamete banks and fertility clinics collecting gametes to maintain each donor's identifying information, medical history, and screening and testing records and to preserve source-facility information when gametes are received from another bank or clinic.